Race Oncology Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAONF research report →
Companywww.raceoncology.com
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations.
- CEO
- Daniel Tillett
- IPO
- 2021
- HQ
- Sydney, NSW, AU
Price Chart
Valuation
- Market Cap
- $451.73M
- P/E
- -46.10
- P/S
- 583.78
- P/B
- 18.36
- EV/EBITDA
- -42.73
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 49.76%
- Op Margin
- -1294.94%
- Net Margin
- -1190.78%
- ROE
- -47.44%
- ROIC
- -33.36%
Growth & Income
- Revenue
- $6.04M · 50.96%
- Net Income
- $-4,787,258 · 65.36%
- EPS
- $-0.03 · 66.90%
- Op Income
- $-3,771,834
- FCF YoY
- 52.08%
Performance & Tape
- 52W High
- $2.60
- 52W Low
- $0.83
- 50D MA
- $1.22
- 200D MA
- $1.22
- Beta
- 1.91
- Avg Volume
- 1
Get TickerSpark's AI analysis on RAONF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RAONF Coverage
We haven't published any research on RAONF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RAONF Report →